Former Michigan GOP gubernatorial candidate Tudor Dixon joined ‘Fox & Friends First’ to discuss her reaction to Sen. John Fetterman’s open-mindedness to Trump’s Cabinet
Look outside the U.S. for the next Trump trade: Jay Pelosky
Donald Trump’s win in the recent U.S. presidential election has, unsurprisingly, been a boon for U.S. equities. But his victory may ultimately prove to
Transcript: Trump Allies Trade Insults as His Latest Pick Rattles MAGA
An interview with political scientist Julia Azari, who explains how Trump’s extreme cabinet picks show he’s wildly overreading his “mandate”—and why that’s so dangerous.
Will Trump bend the Senate to his will? A Q&A with Dr. Ross Baker
To better understand that strategy, measure the Senate’s appetite to obey in advance, and gauge its sense of self-preservation, we turned to historian Dr.
Democrats Are Against Trump. But What Exactly Are They For?
A united Democratic Party with a clear message would have handily won this year’s election. But that would have required a willingness to reckon
The problems and opportunities with Trump’s mass deportation plan
Donald Trump’s promised mass deportation plan is supposed to get rolling on the first day of his presidency, but major challenges stand in the
Stocks This Week: Buy Energizer And Shopify
First, Thanksgiving provides a boost and then the Christmas-New Year bullish effect kicks in The December 15-January 11 interval is one of the most
These Stocks Are Moving the Most Today: Super Micro Computer, Snowflake, Palantir, MicroStrategy, Peabody Energy, and More
Shares of Super Micro Computer extend last week’s sharp gains, Snowflake stock is upgraded, and MicroStrategy may soon unveil a fresh purchase of Bitcoin.
Disney’s Magic Strategy: Reinventing the House of Mouse
Disney’s stock has seen a recent surge, catching the eye of investors and prompting optimistic re-evaluations from Disney’s analyst community. With the streaming division
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $23